TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30833645

Group type: EXPERIMENTAL
Intervention: Coloplast Titan
Number of subjects: 100

Group type: COMPARATOR
Intervention: Coloplast Titan Touch
Number of subjects: 100

Group type: COMPARATOR
Intervention: AMS 700
Number of subjects: 100
Study: 31265756

Group type: EXPERIMENTAL
Intervention: Parenteral sedation
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Age 65 years and older
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: More than one type of parenteral sedation administered within 60 minutes
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 904
Study: 28425449

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo-pill treatment
Number of subjects: 169

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 169
Study: 25458637

Group type: EXPERIMENTAL
Intervention: rhG‐CSF plus empirical antibiotics (Group I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Empirical antibiotics alone (Group II)
Number of subjects: 56
Study: 23057583

Group type: EXPERIMENTAL
Intervention: Positive mood with high arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive mood with low arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood with high arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood with low arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral mood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 21467561

Group type: EXPERIMENTAL
Intervention: Revised Preanesthetic Set‐Up
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regional anesthesia technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Higher case loads (≥5 cases scheduled)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Set-up completed by attending anesthesiologists
Number of subjects: 200
Study: 17391746

Group type: EXPERIMENTAL
Intervention: Phonological neighbor (mouse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated word (lamp)
Number of subjects: 0
Study: 17117001

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (3 times a week for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 15146224

Group type: EXPERIMENTAL
Intervention: Breast cancer survivors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy women
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 11587368

Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: MRC trial (specific to autograft)
Number of subjects: 1200
Study: 9205016

Group type: EXPERIMENTAL
Intervention: Nicorandil 5 mg tid
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8204996

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1168

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1168
Study: 3330528

Group type: EXPERIMENTAL
Intervention: ST 567 3 X 30 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propranolol 3 X 40 mg
Number of subjects: 48
Study: 30924578

Group type: EXPERIMENTAL
Intervention: fast-acting insulin aspart (faster aspart)
Number of subjects: 236

Group type: COMPARATOR
Intervention: basal-only insulin
Number of subjects: 236
Study: 28620916

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: All groups (Ketamine 0.2 mg/kg, Ketamine 0.4 mg/kg, Saline)
Number of subjects: 135
Study: 26571892

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Tianshu (ST 25), Fujie (SP 14) with dense‐disperse wave (2Hz/15 Hz, 0.1 to 1.0 mA) and Shangjuxu (ST 37) needled, treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham‐EA) at sites lateral to Tianshu (ST 25) and Fujie (SP 14), and shallow needling at lateral Shangjuxu (ST 37), treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Number of subjects: 70
Study: 24295403

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21397770

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days
Number of subjects: 202

Group type: COMPARATOR
Intervention: Vehicle administered twice daily for 3 days
Number of subjects: 202
Study: 18454508

Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 382

Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a plus ribavirin in genotype 2 patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a plus ribavirin in genotype 2 patients
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: 12 weeks of peginterferon alpha-2a plus ribavirin in genotype 3 patients
Number of subjects: 382

Group type: COMPARATOR
Intervention: 24 weeks of peginterferon alpha-2a plus ribavirin in genotype 3 patients
Number of subjects: 382
Study: 16814647

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 14508214

Group type: COMPARATOR
Intervention: Predominantly formula fed until term chronological age (PFF-T, n = 119)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Predominantly human milk fed until term chronological age (PHM-T, n = 43)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: >= 50% energy from human milk before hospital discharge (>= 50% HM, n = 98)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: < 50% of energy from human milk before hospital discharge (< 50% HM, n = 203)
Number of subjects: 463
Study: 11006795

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/day orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride
Number of subjects: 0
Study: 10163482

Group type: EXPERIMENTAL
Intervention: Jet spacer with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard actuator with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Number of subjects: 36
Study: 1614687

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 426

Group type: COMPARATOR
Intervention: Anti-DIM medication, vitamins, and combined regimen
Number of subjects: 426
Study: 6692967

Group type: EXPERIMENTAL
Intervention: Peroral iron therapy (200 mg Fe++ daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no iron therapy)
Number of subjects: 122
Study: 30926104

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with orthodontic treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo group (simulated LLLT with orthodontic treatment)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (orthodontic treatment only)
Number of subjects: 84
Study: 29172851

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control (no adjuvant radiotherapy)
Number of subjects: 228
Study: 26705884

Group type: EXPERIMENTAL
Intervention: Low cadence cycling at 20 RPM
Number of subjects: 17

Group type: COMPARATOR
Intervention: High cadence cycling at 50 RPM
Number of subjects: 17
Study: 24481962

Group type: EXPERIMENTAL
Intervention: Medical antishock trousers (inflated to 70 mmHg) during head-up tilt (HUT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medical antishock trousers (inflated to 70 mmHg) during head-down tilt (HDT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no medical antishock trousers) during head-up tilt (HUT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no medical antishock trousers) during head-down tilt (HDT)
Number of subjects: 12
Study: 22892585

Group type: EXPERIMENTAL
Intervention: Avagacestat 25 mg daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Avagacestat 100 mg daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Avagacestat 125 mg daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 19858136

Group type: EXPERIMENTAL
Intervention: Primary PCI with combined proximal embolic protection and thrombus aspiration
Number of subjects: 206

Group type: COMPARATOR
Intervention: Primary PCI alone (Control)
Number of subjects: 206
Study: 17389702

Group type: EXPERIMENTAL
Intervention: Lugol solution treatment (group 1, n = 17)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No preoperative treatment with Lugol solution (group 2, n = 19)
Number of subjects: 36
Study: 15606696

Group type: EXPERIMENTAL
Intervention: Ever smoked (current or former)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked daily
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Duration of smoking
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Duration of diabetes
Number of subjects: 299
Study: 12131078

Group type: EXPERIMENTAL
Intervention: Gastrografin meal and follow-through study
Number of subjects: 124

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 124
Study: 10396539

Group type: EXPERIMENTAL
Intervention: Doctor/Dietitian group
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Dietitian group
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 273
Study: 7572657

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no ultrafiltration)
Number of subjects: 21
Study: 2269915

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (BCP) ceramic
Number of subjects: 137

Group type: COMPARATOR
Intervention: Open flap curettage
Number of subjects: 137

Group type: COMPARATOR
Intervention: Autogenous bone implant
Number of subjects: 137
Study: 6988947

Group type: EXPERIMENTAL
Intervention: Tinidazole and doxycycline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Doxycycline alone
Number of subjects: 42
Study: 29159691

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC) and hydroxytyrosol (HT) loaded chitosan nanoparticles (CSNPs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle samples (aqueous (AQ) cream)
Number of subjects: 10
Study: 30031089

Group type: EXPERIMENTAL
Intervention: STEPS intervention (Social problem-solving training program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food for Life (attention-control nutrition intervention)
Number of subjects: 0
Study: 26990559

Group type: EXPERIMENTAL
Intervention: Rye kernel bread (RKB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White wheat flour based bread (WWB)
Number of subjects: 0
Study: 23374589

Group type: EXPERIMENTAL
Intervention: Biatain-Ag (silver-releasing dressing)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Biatain (non silver-releasing dressing)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Biatain-Ag (for subgroup with poor healing prognosis)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Biatain (for subgroup with poor healing prognosis)
Number of subjects: 181
Study: 22052102

Group type: COMPARATOR
Intervention: Control (unloaded cycling)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Moderate (6-min moderate intensity)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Heavy (6-min heavy intensity)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: S2 (2-min severe intensity)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: S4 (4-min severe intensity)
Number of subjects: 7
Study: 19064973

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks for two cycles, followed by cisplatin 40 mg/m(2)/wk concurrent with radiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel-cisplatin followed by CRT
Number of subjects: 65
Study: 17115155

Group type: EXPERIMENTAL
Intervention: Shed blood retransfusion (autotransfusion)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no autotransfusion)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (autotransfusion and control)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 14997082

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 30 mg x kg(‐1)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Tranexamic acid 15 mg x kg(‐1) followed by infusion of 1 mg x kg(‐1) h(‐1)
Number of subjects: 250
Study: 12149056

Group type: EXPERIMENTAL
Intervention: Radiotherapy (12 Gy of 6‐mV photons in 6 fractions)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 199
Study: 10405472

Group type: EXPERIMENTAL
Intervention: Sealant restorations
Number of subjects: 164

Group type: COMPARATOR
Intervention: Light cured glass-ionomer cement
Number of subjects: 164

Group type: COMPARATOR
Intervention: Larger composite restorations
Number of subjects: 164
Study: 7751258

Group type: EXPERIMENTAL
Intervention: Lithium (mean optimal daily dose: 1,248 mg, mean serum level: 1.12 mEq/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2346341

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Biosynthetic human growth hormone (r-hGH)
Number of subjects: 26
Study: 341338

Group type: EXPERIMENTAL
Intervention: Clotrimazole 7-day treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clotrimazole 14-day treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: Miconazole nitrate 14-day treatment
Number of subjects: 150
Study: 31612359

Group type: EXPERIMENTAL
Intervention: Inhaled methoxyflurane 3 mL
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard analgesic treatment (SAT) - IV morphine 0.1 mg/kg for severe pain (NRS ≥ 7); IV paracetamol 1 g or IV ketoprofen 100 mg for moderate pain (NRS 4-6)
Number of subjects: 272
Study: 28342723

Group type: EXPERIMENTAL
Intervention: Eccentric overload squat training (six weeks) followed by three consecutive days of running.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CONT) performing three consecutive days of running without prior eccentric training.
Number of subjects: 20
Study: 25537465

Group type: EXPERIMENTAL
Intervention: Prosaccades with lower probability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades with varying trial-type probability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Runs with larger probability of antisaccade trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior antisaccade trial
Number of subjects: 0
Study: 24749263

Group type: EXPERIMENTAL
Intervention: ERAS group (n = 25) with patient‐controlled epidural analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25) with multimodal analgesia (paracetamol, tramadol, ketoprofen)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 20607600

Group type: EXPERIMENTAL
Intervention: Total vegetable intake
Number of subjects: 3080

Group type: EXPERIMENTAL
Intervention: Total vegetable intake among women taking tamoxifen
Number of subjects: 3080

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake among women taking tamoxifen
Number of subjects: 3080

Group type: EXPERIMENTAL
Intervention: Cruciferous vegetable intake above the median and highest tertile of total vegetable intake among women using tamoxifen
Number of subjects: 3080
Study: 19672007

Group type: EXPERIMENTAL
Intervention: Extension-oriented exercise program conducted by a physical therapist
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ergonomic brochure (Control)
Number of subjects: 71
Study: 15927414

Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiotherapy (RT)
Number of subjects: 714

Group type: COMPARATOR
Intervention: No further treatment (controls)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Postoperative pelvic radiotherapy (RT) excluding Grade 1 with superficial myometrial invasion
Number of subjects: 714

Group type: COMPARATOR
Intervention: No further treatment (controls) excluding Grade 1 with superficial myometrial invasion
Number of subjects: 714
Study: 10553846

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 9 mg with fentanyl 20 microg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Plain bupivacaine 9 mg with fentanyl 20 microg
Number of subjects: 76
Study: 8744464

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 1 g every 12 hours for two doses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g every 24 hours for two doses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 20
Study: 1928271

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: COMPARATOR
Intervention: Tobramycin 0.3%
Number of subjects: 288
Study: 6350878

Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard therapy (azathioprine and prednisone)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone (with kidneys perfused by machine for longer than 24 hours)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone (with surgical anastomosis time longer than 45 minutes)
Number of subjects: 209
Study: 30615299

Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neutral insoles
Number of subjects: 62
Study: 29800529

Group type: EXPERIMENTAL
Intervention: Unilateral strength training with eccentric contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 27167669

Group type: EXPERIMENTAL
Intervention: Enteral feeding for 1 week in healthy volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral feeding for 2 weeks in patients with Crohn's disease
Number of subjects: 0
Study: 25528932

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Continuous Moderate Exercise (CME)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 88
Study: 22100536

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 981

Group type: COMPARATOR
Intervention: Control
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: MAC adjudicated causes of death
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: MAC vs SI agreement
Number of subjects: 981
Study: 20203376

Group type: EXPERIMENTAL
Intervention: Conventional TENS (one-time trial management program)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Conventional TENS (one-week trial management program)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (fifteen healthy children)
Number of subjects: 27
Study: 17657970

Group type: EXPERIMENTAL
Intervention: Aerosol therapy using 'Dovolenskaya' mineral water
Number of subjects: 0
Study: 15831534

Group type: EXPERIMENTAL
Intervention: Moderate-intensity shivering (5 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity shivering (10 degrees C)
Number of subjects: 0
Study: 12019591

Group type: EXPERIMENTAL
Intervention: Physical activity programs at worksites
Number of subjects: 8
Study: 9445330

Group type: EXPERIMENTAL
Intervention: EuroQol
Number of subjects: 2253

Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Both EuroQol and SF‐36
Number of subjects: 2253
Study: 7625344

Group type: EXPERIMENTAL
Intervention: 0.8 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.0 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1.2 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 1.2 g.kg body wt-1.d-1 of a high-quality mixed protein diet (80% from animal sources)
Number of subjects: 7
Study: 30703179

Group type: EXPERIMENTAL
Intervention: Pain Cards (photographic images co-created by an artist and chronic pain patients)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pain Cards
Number of subjects: 119
Study: 29151701

Group type: EXPERIMENTAL
Intervention: Transcatheter selective SMA urokinase infusion therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 40
Study: 25052366

Group type: EXPERIMENTAL
Intervention: PPC-5650
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 23266205

Group type: EXPERIMENTAL
Intervention: Modified technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 110
Study: 21699794

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) in a maximum of 3 infusions of 1000 or 500 mg iron
Number of subjects: 485

Group type: COMPARATOR
Intervention: Iron sucrose (IS) with Ganzoni-calculated dosages in up to 11 infusions of 200 mg iron
Number of subjects: 485
Study: 19194376

Group type: EXPERIMENTAL
Intervention: Cytidine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 17531572

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus provisional glycoprotein IIb/IIIa blockade
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Heparin plus planned glycoprotein IIb/IIIa blockade
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Anemic patients
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Nonanemic patients
Number of subjects: 1371